Nirmatrelvir is a potent and selective inhibitor of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus …

Simple Summary Treatments for coronavirus disease-2019 (COVID-19) have utilized a
variety of medications, including antivirals, immunomodulators, and other therapeutics such …

Early in the COVID-19 pandemic, there was a desperate need for a therapy against the
scourge which was decimating health care systems worldwide. As systems became …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing the coronavirus
disease 2019 (COVID-19), has provoked more than six million deaths worldwide and …

COVID-19 has taken a huge toll on our lives over the last 3 years. Global initiatives put
forward by all stakeholders are still in place to combat this pandemic and help us learn …

Background Since the beginning of the COVID-19 pandemic, therapeutic options for treating
COVID-19 have been investigated at different stages of clinical manifestations. Considering …

Objectives: We aimed to evaluate the high-quality literature on the frequency and nature of
major adverse cardiac events (MACE) associated with either hydroxychloroquine (HCQ) or …

Background Camostat inhibits severe acute respiratory syndrome coronavirus 2 (SARS-CoV-
2) infection in vitro. We studied the safety and efficacy of camostat in ACTIV-2/A5401, a …

Aprotinin (APR) was discovered in 1930. APR is an effective pan-protease inhibitor, a typical
“magic shotgun”. Until 2007, APR was widely used as an antithrombotic and anti …

Background. Camostat inhibits severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) infection in vitro. We studied the safety and efficacy of camostat in ACTIV-2/A5401, a …